Release Date: 11-Feb-2025
In 2024, Roche’s Columvi, a bispecific antibody for lymphoma, recorded sales of over US$ 188 million, marking an exceptional growth of over 500% from US$ 30 million in 2023. This surge represents one of the largest sales increases in Roche’s drug portfolio, highlighting the growing adoption of Columvi in treating relapsed or refractory follicular lymphoma. The strong market performance reflects increasing physician confidence and expanding patient access. As a bispecific antibody, Columvi continues to gain momentum, reinforcing Roche’s leadership in innovative oncology treatments and solidifying its place in the competitive landscape of targeted lymphoma therapies.
For Global Bispecific Antibodies Report Sample Contact [email protected]